UC Davis Health investigators, thanks to a recent federal grant, are preparing to test a promising new antibody cocktail, known as REGN-COV2, as a prevention and treatment for SARS-CoV-2, the virus behind COVID-19. Led by Dr. Timothy Albertson, chairman of internal medicine and specialist in pulmonary and critical care, the team gears up for the randomized, controlled trial sponsored by Regeneron, the developer of REGN-COV2.
The study will be conducted at UC Davis Medical Center in Sacramento and is supported by a federal grant for approximately $291,000 in addition to investments made by Regeneron. UC Davis’ Dr. Albertson was awarded the grant from the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. The Phase 1/2 study #NCT04426695 estimated primary completion date is January 29, 2021.
The Investigational Product
This product is known as REGN-COV2, which is actually a combination of two monoclonal investigational products called REGN10933 and REGN10987. Combined as a Phase 1, 2 randomized, double-blinded, placebo-co...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).